SBIR/STTR Research Award

Novel 5'-end tagging of mRNA for cDNA synthesis or RACE

Award identifier cff8c6c45b6c416150e30751a5a529d56257b9b9569b4165dd484d1e9c7a1f77Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$92,662

Program and phase

SBIR · Phase I

Award year

2001

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
ACTIVE MOTIF, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
N7GVF5GCF3A6
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (Applicant's abstract): In this application we will discuss the rationale for the development of a novel method for chemically tagging a synthetic oligonucleotide to the 5'-end of full-length mRNAs using the cap structure (7-methyl guanosine triphosphate, m7Gppp). There are two major technical limitations in full-length cDNA library construction. The first is reduced efficiency of the reverse transcriptase reaction and the second limitation is the inability to efficiently select only full-length cDNA. This is compounded by the need to use RNase H to generate RNA primers for second strand synthesis, which biases against the isolation full-length cDNAs. Current RACE methods (Rapid Amplification of cDNA ends) and commercial kits to isolate full-length cDNAs are technically dificule whith variable at best. In this proposal we have designed a procedure which will address some of the problems inherent with current protocols. The technique can be used as either a 5'-RACE method or a full-length cDNA library construction method. By attaching a ribo-oligonucleotide through the morpholino-nucleoside residue to the 5'-capped end of mRNA, the reverse transcriptase can read through the cap structure, and using the attached ribo-oligonucleotide as a template, continuing systhesis of first strand cDNA to the end of this oligo. The complementary sequence to the ribooligonucleotide becomes attached to the 3'-end of the cDNA, presenting a known priming site for second strand synthesis to generate full-length double strand cDNA, This method is especially advantageous in that it does not require an RNase H step to generate primers for second strand synthesis, which in itself biases against 5'-end identification. PROPOSED COMMERCIAL APPLICATION: The ultimate goal will be to generate an efficient method for specifically tagging the 5'-cap structure of full-length cDNA. This technology will hopefully supercede the current technologies, which are technically difficult and inefficient. Quality full-length cDNA libraries and 5'-EST libraries will be developed. These libraries will result in the identification of novel 5' -untranslated regions and longer and rarer genes.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

23 SBIR/STTR records share this UEI (2001–2025). Reported award amounts total $5,925,376. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, National Science Foundation

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.